123 related articles for article (PubMed ID: 6291099)
1. Degradation of cholecystokinin octapeptide, related fragments and analogs by human and rat plasma in vitro.
Koulischer D; Moroder L; Deschodt-Lanckman M
Regul Pept; 1982 Aug; 4(3):127-39. PubMed ID: 6291099
[TBL] [Abstract][Full Text] [Related]
2. Degradation of cholecystokinin-like peptides by a crude rat brain synaptosomal fraction: a study by high pressure liquid chromatography.
Deschodt-Lanckman M; Bui ND; Noyer M; Christophe J
Regul Pept; 1981 Apr; 2(1):15-30. PubMed ID: 6262880
[TBL] [Abstract][Full Text] [Related]
3. Cholecystokinin cleavage to cholecystokinin-octapeptide in vivo and in vitro: accelerated cleavage in acute pancreatitis.
Springer CJ; Calam J
Gastroenterology; 1988 Jul; 95(1):143-50. PubMed ID: 2453390
[TBL] [Abstract][Full Text] [Related]
4. Degradation of human gastrin and CCK by endopeptidase 24.11: differential behaviour of the sulphated and unsulphated peptides.
Pauwels S; Najdovski T; Dimaline R; Lee CM; Deschodt-Lanckman M
Biochim Biophys Acta; 1989 Jun; 996(1-2):82-8. PubMed ID: 2736261
[TBL] [Abstract][Full Text] [Related]
5. Cholecystokinin octa- and tetrapeptide degradation by synaptic membranes. I. Evidence for competition with enkephalins for in vitro common degradation pathways.
Deschodt-Lanckman M; Bui ND
Peptides; 1981; 2 Suppl 2():113-8. PubMed ID: 6283489
[TBL] [Abstract][Full Text] [Related]
6. Cholecystokinin octa- and tetrapeptide degradation by synaptic membranes. II. Solubilization and separation of membrane-bound CCK-8 cleaving enzymes.
Deschodt-Lanckman M; Bui ND; Koulischer D; Paroutaud P; Strosberg AD
Peptides; 1983; 4(1):71-8. PubMed ID: 6306618
[TBL] [Abstract][Full Text] [Related]
7. Products of cholecystokinin (CCK)-octapeptide proteolysis interact with central CCK receptors.
Steardo L; Knight M; Tamminga CA; Chase TN
Neurosci Lett; 1985 Mar; 54(2-3):319-25. PubMed ID: 2986058
[TBL] [Abstract][Full Text] [Related]
8. Development of a sensitive and specific assay system for cholecystokinin tetrapeptide.
Merani S; Palmour RM; Bradwejn J; Berezowska I; Vaccarino FJ; Gutkowska J
Peptides; 1997; 18(6):869-75. PubMed ID: 9285937
[TBL] [Abstract][Full Text] [Related]
9. Effects of cholecystokinin (CCK-33) and its fragments, C-terminal octapeptide (CCK-8) and C-terminal tetrapeptide (CCK-4), on the circulatory system of diabetic rats.
Fiedorowicz RJ; Wiśniewski K
Pol J Pharmacol Pharm; 1989; 41(6):561-72. PubMed ID: 2485904
[TBL] [Abstract][Full Text] [Related]
10. CCK-58 is the only detectable endocrine form of cholecystokinin in rat.
Reeve JR; Green GM; Chew P; Eysselein VE; Keire DA
Am J Physiol Gastrointest Liver Physiol; 2003 Aug; 285(2):G255-65. PubMed ID: 12686511
[TBL] [Abstract][Full Text] [Related]
11. Cholecystokinin octapeptide levels in rat brain are changed after subchronic neuroleptic treatment.
Frey P
Eur J Pharmacol; 1983 Nov; 95(1-2):87-92. PubMed ID: 6141947
[TBL] [Abstract][Full Text] [Related]
12. Hydrolysis of the C-terminal octapeptide of cholecystokinin by rat kidney membranes: characterization of the cleavage by solubilized endopeptidase-24.11.
Najdovski T; Collette N; Deschodt-Lanckman M
Life Sci; 1985 Sep; 37(9):827-34. PubMed ID: 3897758
[TBL] [Abstract][Full Text] [Related]
13. The effect of cholecystokinin (CCK-33) and C-terminal fragments of cholecystokinin: CCK-8 and CCK-4 on the cardiovascular system in rats.
Wiśniewska RJ; Wiśniewski K
Gen Pharmacol; 1996 Jan; 27(1):159-63. PubMed ID: 8742514
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of a radioimmunoassay for cholecystokinin in human plasma.
Cantor P
Scand J Clin Lab Invest; 1986 May; 46(3):213-21. PubMed ID: 2424076
[TBL] [Abstract][Full Text] [Related]
15. Plasma cholecystokinin-octapeptide like immunoreactivity in patients with hepatic cirrhosis.
Kanayama S; Himeno S; Higashimoto Y; Yamasaki Y; Kitani T; Tarui S
Life Sci; 1987 Oct; 41(16):1915-20. PubMed ID: 3657391
[TBL] [Abstract][Full Text] [Related]
16. Antinociceptive action of cholecystokinin octapeptide (CCK 8) and related peptides in rats and mice: effects of naloxone and peptidase inhibitors.
Hill RG; Hughes J; Pittaway KM
Neuropharmacology; 1987 Apr; 26(4):289-300. PubMed ID: 3295578
[TBL] [Abstract][Full Text] [Related]
17. Aging and panicogenic response to cholecystokinin tetrapeptide: an examination of the cholecystokinin system.
Flint A; Bradwejn J; Vaccarino F; Gutkowska J; Palmour R; Koszycki D
Neuropsychopharmacology; 2002 Oct; 27(4):663-71. PubMed ID: 12377403
[TBL] [Abstract][Full Text] [Related]
18. Characterization of cholecystokinin binding sites in rat cerebral cortex using a 125I-CCK-8 probe resistant to degradation.
Praissman M; Martinez PA; Saladino CF; Berkowitz JM; Steggles AW; Finkelstein JA
J Neurochem; 1983 May; 40(5):1406-13. PubMed ID: 6300335
[TBL] [Abstract][Full Text] [Related]
19. Binding specificity of the mouse cerebral cortex receptor for small cholecystokinin peptides.
Steigerwalt RW; Williams JA
Regul Pept; 1984 Jan; 8(1):51-9. PubMed ID: 6326203
[TBL] [Abstract][Full Text] [Related]
20. Chronotropic actions of cholecystokinin octapeptide on the rat heart.
Marker JD; Roberts ML
Regul Pept; 1988 Mar; 20(3):251-9. PubMed ID: 3363182
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
